本帖最后由 成长的烦恼 于 2012-6-27 20:19 编辑 7 @. [: |3 N6 T" K8 j& x
# c6 L, f$ B) [9 {: p3 [' A) ?clinicaltrials上的三期临床链接
! x3 l5 G p/ H7 Q
" m+ c& a1 @& ]& j, hhttp://clinicaltrials.gov/ct2/sh ... mp;show_locs=Y#locn
- }0 M3 O+ o8 K) ]# } Q% @1 f# H: l& ~: r, P3 m" R) F+ E: s; Z
中国参加临床实验的城市9 Y1 T0 I( L6 e# J" C& B4 E ?
& n& T, M9 n1 b( y6 i/ jChina, Guangdong 5 r: H4 s5 u, H
0 Q+ w1 o; U; `7 }Guangzhou, Guangdong, China, 510515
% h/ l) v( @4 t) P( z' F5 U % |, T, y% |- I6 F; D4 r
Guangzhou, Guangdong, China, 510060
: V: d3 B' M5 J" U- s8 j' LChina, Jiangsu 1 c# h4 \/ A$ z- ^9 s
6 k$ `! o1 y1 m; p
Nanjing, Jiangsu, China, 210009 / I) ?+ o6 j4 Z3 ~ c
`6 S; I% z0 `$ a0 [. jNanjing, Jiangsu, China, 210002 ; H6 T% `* [ ~' v6 f7 ]
China, Shandong
' P, g" f* i+ m1 W7 z' ~' I
* i+ n4 p( D, s' f$ tQingdao, Shandong, China, 266003 ( n. H; ?: \/ K+ W) D p. n: i
China $ w9 |! y# h% T9 }" {
; ]% b2 _+ h: P" U
Beijing, China, 100021 & } d9 ^2 p7 o+ v
8 S$ X1 d+ c7 k: c9 G. w. OBeijing, China, 100071
5 k0 y. r4 q8 O+ ^0 V ) L5 I9 s; ^8 Q
Changchun, China, 130021
9 q9 J& d3 `7 o3 ?9 r
( z! Y! @) f ]8 WChongqing, China, 400042
% ~3 y2 D- ]# y0 r
7 C3 t: m* u: P' {Chongqing, China, 400038 * a D/ O/ O; | W3 P
% D9 t) C0 s9 g+ ^' q5 v
Fuzhou, China, 350014 8 T, q1 `: h% k2 z
6 z+ T, b k; K7 lFuzhou, China, 350025
" s0 G# C& i9 P
4 S, j' }+ v. U1 h: L" {Ha'erbin, China, 150040
; a1 p4 M4 P5 w# V- E
) H! h# A! F8 W7 o3 L8 cHanghzou, China, 310009
: o2 ]/ R3 { O; L8 K! C q1 e . c& P* i! b/ F
Shanghai, China, 200001
( H0 j0 e& Y$ ~* [$ R7 k
1 j% K d% b( _$ W$ `2 `Shanghai, China, 200030
: o' M9 Q8 n% `4 ^
4 e: p5 K- L+ S9 xTianjin, China
- e3 x# s) Q( \
/ I" {4 t; Y; c+ D D" R5 p7 J该实验已停止招募,重新开的临床请见临床专用贴。 |